Preliminary evaluation of a broad-scope tumor targeting alkylphosphocholine chelate in canines with spontaneous tumors.

Conclusions: Our results demonstrate the ability of NM600 to target diverse canine tumors to safely deliver therapeutic 90Y-NM600 doses. These provide guidance for further dose escalation studies and future Phase 1 human clinical trials.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Massey, C., Hernandez, R., Grudzinski, J., Marsh, I., Aluicio-Sarduy, E., Turek, M., Magee, K., Engle, J., Morris, Z., Bednarz, B., Vail, D., Weichert, J. Tags: Basic Oncology & amp; Translational IV Source Type: research